Business Briefs: Seagen appoints new CEO; new research president | HeraldNet.com

Seagen, a prominent cancer therapy developer based in Bothell, has appointed David R. Epstein as its new CEO, succeeding co-founder Clay Siegall, who resigned following domestic violence allegations. With over 30 years of experience in the pharmaceutical industry, including a significant tenure at Novartis, Epstein's leadership is expected to drive Seagen's mission to develop innovative cancer treatments. The company has a strong portfolio of approved therapies and is dedicated to enhancing patient outcomes through cutting-edge research and development. In parallel, Eviation Aircraft has made headlines by surpassing $2 billion in orders for its all-electric commuter plane, Alice, marking a significant achievement in sustainable aviation technology.

This surge in orders demonstrates the market's growing demand for eco-friendly alternatives in transportation, aligning with global trends towards sustainability and innovation in the aerospace industry. Both Seagen's leadership change and Eviation's order volume reflect the dynamic nature of business in the Pacific Northwest, underscoring the region's role as a hub for biotech and aerospace advancements while addressing health and environmental challenges through innovative solutions.